

1 Original Research Article  
2 **Accuracy of Magnetic Resonance Imaging (MRI) in**  
3 **Detecting Breast Tumors**

4  
5 **ABSTRACT**  
6

**Aims:** The aim of this study was to evaluate the accuracy of magnetic resonance imaging (MRI) in characterizing breast abnormalities and tumors, in comparing to other diagnostic modalities and histopathological findings.

**Study Design:** This prospective study included 254 patients (14 males and 240 females; ages range between 15-78 years) underwent breast MRI examination.

**Place and Duration of Study:** This study was conducted in different MRI medical centers in Khartoum, Sudan between June 2014 and July 2016.

**Methodology:** Patients were examined using two sequences of MRI; routine and dynamic contrast enhanced MRI (DCE-MRI). Signal intensities were evaluated from different MRI sequences in different tumors; the histopathology result was used as a reference for each case.

**Results:** The sensitivity and specificity of MRI were (82.6%) and (73.2%) respectively. In addition, the breast cancer was more enhanced with fat suppression images. DCE-MRI has been shown to be more sensitive than routine sequences in detecting ductal carcinoma in situ (DCIS). Image subtraction technique showed that breast cancer has heterogeneous features (89.9%), and ring enhancement was clearly seen on (8.7%). DCE-MRI has been used to evaluate focal breast lesions. Adding information derived from the kinetic curve type of architectural features of a lesion, improves the specificity of breast MRI. On the other hand, it revealed that most cases of cancer represented on type 111 curves or rapid wash out. However, quantitative measurements of kinetic curve type resulted in significantly higher diagnostic performance and increasing specificity of MRI.

**Conclusion:** The accuracy of MRI in this study was more than other imaging modalities in characterizing breast abnormalities and tumors. Therefore, it offers a new method to detect breast cancer in its early stage, and help improve the survival rate.

7  
8 *Keywords: Accuracy, breast tumors, histopathology, imaging, MRI, protocols.*  
9

10 **1. INTRODUCTION**  
11

Breast cancers are the most common type of cancer among women in the industrialized world. A woman's average lifetime risk for developing breast cancer in the United States is 1 in 8 [1]. In Sudan breast cancer is about (29%-34.5%) of all women's cancers [2]. Breast cancer cannot be prevented at the present time; however, early detection of breast cancer provides the best chance of survival and early treatment options [2]. Because early breast cancer is asymptomatic, the only way to detect it is through screening [3].

Different methods have been used in the diagnosis of breast cancer, including self-examination and clinical examination, mammography, ultrasound, magnetic resonance imaging (MRI) modality, follow up methods and biopsy [2]. Regular breast self-exam (BSE), can be an important way to find a breast cancer early, when it's more likely to be treated successfully. In spite of the fact that breast is superficial organ which is amenable to clinical examination, may not reveal any pathological problems, so that clinical examination would not easily detect sub centimeter lesions if they are deeply situated within the breast and would not easily and confidently differentiate between benign and malignant breast lesion [4]. In certain situation, clinical examination, mammography, and ultrasonography have some limitations, either due to factors in the breast parenchyma such as dense breast in young females, post-operative changes or effect of irradiation or factors in modality itself, such as the inability of mammography to demonstrate deep part of the breast and operator dependency of ultrasound [5].

In diagnosing breast abnormalities and tumors, there is a need for a specific diagnostic modality to reach an accurate diagnosis of these abnormalities, such as mammography, which is an effective means of

31 detecting and diagnosing breast cancer. It decreases breast cancer mortality by 1/3 when used as  
32 screening, however, reported high false negative from (4%-34%) [6]. Taking in mind that an abnormal  
33 screening mammogram requires a diagnostic test to confirm whether cancer is present, many women  
34 who do not have cancer will undergo these unnecessary diagnostic tests [3]. In these difficult situations, a  
35 biopsy may be restored to as a diagnostic method. In the last few years, magnetic resonance (MR)  
36 imaging has been introduced as a promising method for diagnosis of breast neoplasms particularly when  
37 dynamic contrast gadolinium (Gd) enhancement studies are used [7,8]. Several studies have explored a  
38 multi-parametric approach to breast imaging that combines analysis of traditional contrast enhancement  
39 patterns and lesion architecture with novel methods such as diffusion, perfusion, and spectroscopy to  
40 increase the specificity of breast MRI studies [9]. The value of dynamic contrast enhanced MRI (DCE-  
41 MRI) is dependent on its ability to demonstrate intrinsic differences between varieties of issues that affect  
42 contrast media behavior. Evidence is mounting that DCE-MRI measurements correlate with immune  
43 histochemical surrogates of tumor angiogenesis [9].  
44 This study aimed to evaluate the accuracy of MRI in characterizing breast abnormalities and tumors, and  
45 to compare the findings with the other diagnostic modalities and histopathological findings.  
46  
47

## 48 2. MATERIAL AND METHODS

### 49 2.1 Patient samples

50 The study was conducted in 254 patients, 250 were female (98.4%) and 4 male (1.6%). The mean age of  
51 all patients was 47 years, age range between 15-78 years. All patients were examined by DCE-MRI.  
52 Clinical examination and full history were taken as well as written informed consent was obtained.  
53 Sudanese patients who were 15 years old or older, with proven breast cancer were eligible for  
54 recruitment. Exclusion criteria were absolute contraindications to MRI, pregnancy or breast feeding,  
55 severe renal failure, known hypersensitivity to gadolinium chelates, inclusion in other clinical trials during  
56 the month before enrollment, and clinical status that would limit data reliability.  
57  
58  
59

### 60 2.2 Breast mammography, ultrasound and biopsy procedure

61 Mammography was performed with at least two views per breast (medio-lateral oblique and cranio-caudal  
62 views) using a low radiation dose digital mammography system (Mammomat, Siemens, Germany).  
63 Additional views or spot compression views were obtained where appropriate.  
64 Breast ultrasound was performed using 7.5-13 MHz probes (high resolution General electric (GE) medical  
65 system, logic 5 expert, Sony Corporation, Japan); the entire breast was systematically examined by the  
66 physician who interpreted the study.  
67 Breast fine needle aspiration biopsy under the guidance of ultrasound, was performed while the patient  
68 lying on back on the examination bed in the ultrasound room. The patient's upper body undressed, with  
69 one arm above the head on the pillow in a comfortable position. One physician applied ultrasound gel on  
70 the breast and the ultrasound transducer (7.5-13 MHz) slowly moved across the breast to show and  
71 identify the lesion. The needle passed through the skin and into the lesion guided by the ultrasound  
72 images. Both local anesthetic and antiseptic liquids were used as the needle is inserted. Less than 1cm  
73 forward and backward, gentle movements with the needle to collect cells or, if the lesion is a cystic in  
74 nature, fluid may be collected. Two or three separate samples are usually taken in this way to ensure a  
75 good sample has been obtained.  
76  
77

### 78 2.3 Breast MRI protocols

79 The breast MRI examination was performed using 1.5 Tesla (General Electric, Milwaukee, WIS, USA)  
80 MRI scanner using phased-array breast surface coil, with patients lying in prone position. The MRI  
81 protocol included an echo-planar DW sequence; for imaging with this sequence the phased-array breast  
82 coil was converted to operate in a linear mode to accommodate the high acquisition speeds (~ 80 kHz).  
83

84 MRI has emerged as an alternative, powerful tool for breast cancer screening as it does not require  
85 exposure to ionizing radiation; it is thus safe to use routinely and more suitable than mammography for  
86 assessing young women. The MRI protocol consisted of the following sequences: 1) Coronal T<sub>1</sub>-weighted  
87 spin echo sequence was carried out for localization purpose and followed by plain sequences using T<sub>1</sub>-  
88 weighted fast spin echo sequence (TR=125msec, TE=5.3msec), in addition to T<sub>2</sub>-weighted fast spin echo  
89 sequence (TR=3740msec, TE=90msec) in axial orientation. A bolus of gadolinium (Gd-DTPA)  
90 (Magnevist, Schering AG Berlin, Germany) was injected manually and intravenously at a dose of (0.1  
91 mmol/kg) followed by a saline flush to ensure that contrast enhanced images could be obtained  
92 immediately after contrast agent injection, 2) Dynamic contrast T<sub>1</sub>-weighted images, then performed using  
93 gradient echo T<sub>1</sub>-weighted image with fat suppression at the following time point at 1 min, 2 min, 4 min,  
94 and 7 min, 3) Post processing subtraction for the MRI image was obtained between the post contrast  
95 imaging showing maximum enhancement and pre-contrast images (in the same axial plane), using the  
96 software subtraction function, and 4) Quantitative analysis was done by placing the region of interest  
97 (ROI) at the most enhanced part with the lesion result in automatically created time/signal curve. The type  
98 of curve (type 1, type 11, type 111), determine the type of tumors. Qualitative analysis of mammography,  
99 ultrasound, and breast MRI was done by three radiologists who were blinded to the clinical, operational  
100 and histopathological examination.

101

## 102 **2.4 MRI image interpretation and criteria for evaluating the presence of breast lesions**

103

104 Conventional T<sub>1</sub> and T<sub>2</sub> weighted images were first examined to detect the presence or absence of  
105 benign lesions (e.g. cysts and fat containing lesions) then T<sub>1</sub> dynamic and subtraction images were  
106 examined to detect the presence or absence of lesion enhancement.

107 In case of lesion enhancement the corresponding non subtracted pre-contrast and post contrast images  
108 in each time point was viewed together and lesions interpretation took place, whether it is a focus, mass  
109 or non-mass like enhancement.

110 In case of mass enhancement evaluation was carried out as follows: 1) Its shape (regular or irregular), 2)  
111 Its border (well defined, ill defined, speculated), 3) Pattern of enhancement (homogenous, heterogeneous  
112 or ring enhancement), 4) The dynamic behavior of the mass with evaluation of the percentage of  
113 enhancement as well as the shape of time/signal intensity curve (type I, type II or type III) was studied, 5)  
114 In case of non-mass like enhancement, its distribution and enhancement pattern were evaluated, and 6)  
115 MRI findings were correlated with histopathological result.

116

## 117 **2.5 Statistical analysis**

118

119 Data were initially summarized in a form of comparison tables and graphs. All statistical calculations were  
120 done using computer program of the standard Statistical Package for the Social Sciences (SPSS Inc.,  
121 Chicago, IL, USA) version 20 for windows.

122

123

## 124 **3. RESULTS**

125

126 The results of this study were obtained from 254 patients; 14 (5.5%) males and 240 (94.5%) female, aged  
127 between 15-78 years old as presented in Figure 1 below. Table 1 demonstrates MRI findings and  
128 histopathological results cross tabulation.




Fig. 1. The distribution of females' age, according to tumors count.

Table 1. MRI findings and histopathology result cross-tabulation

Histopathology	MRI examination finding			Total
	Normal	Benign tumors	Irregular/Suspected Cancers	
Normal	30	11	0	41
Benign	1	62	19	82
Malignant	0	17	114	131
Total	31	90	133	254

The sensitivity of DCE-MRI in detecting breast lesions was (82.7%) and the accuracy was (81.1%), when compared to other diagnostic modalities as mammography or ultrasonography as shown in Table 2.

Table 2. The sensitivity, specificity and accuracy of MRI compared with other imaging modalities

Modality	Specificity (%)	Sensitivity (%)		Accuracy (%)
		Benign	Malignant	
DCE-MRI	(73.2%)	(82.7%)	(82.6%)	(81.1%)
Ultrasound	(75.6%)	(68.0%)	(30.4%)	(48.8%)
Mammography	(73.2%)	(60.0%)	(37.7%)	(50.0%)

In Table 3, T<sub>1</sub> with contrast presented high signal in malignant breast lesions (97.8%). This signal increased after contrast administration. In addition, there was an increase in the signal, when the images that subtracted the tumors were isolated from normal tissues. Such findings were presented in Table 4, and Figure 2. Also, it was found that T<sub>2</sub> has high signal in some benign tumors such as cyst, and duct ectasia (95.1%).

149 **Table 3. T<sub>1</sub>-weighted with contrast and histopathology result cross-tabulation**


Histopathology	T <sub>1</sub> with contrast			Total
	Hyper-signal	Hypo-signal	Iso-signal	
Normal	3	15	23	41
Benign	17	39	19	75
Cancer	115	16	7	138
Total	135	70	49	254

150  
151  
152

**Table 4. Image subtraction result and histopathology cross-tabulation**

Subtraction	Histopathology			Total
	Normal	Benign	Malignant	
Normal	1	3	1	5
Homogeneous	40	42	12	94
Heterogeneous	0	26	113	139
Ring enhances	0	4	12	16
Total	41	75	138	254

153  
154



155 **Fig. 2. Signal intensity in fat suppression images.**

156  
157  
158 Quantitative measurement of kinetic curve type resulted in significantly higher diagnostic performance  
159 when compared with the qualitative assessment, that rapid wash (86.0%) is highly suggested of cancer,  
160 plateau (26.7%) cancer and persistent cancer (1.6%) as depicted in Table 5.

161  
162 **Table 5. Shows curve type in dynamic contrast enhanced MRI (DCE-MRI)**

Curve type	Histopathology			Total
	Normal	Benign	Malignant	
Persistent	2	17	1	20
Plateau	1	13	16	30
Rapid	0	7	43	50
Total	3	37	60	100

#### 163 4. DISCUSSION

164  
165 This study consisted of 254 patients with the aim to evaluate the accuracy of magnetic resonance  
166 imaging (MRI) in characterizing breast abnormalities and tumors, in comparing to other diagnostic  
167 modalities and histopathological findings. The result of this study revealed that the incidence of breast  
168 cancer increased in all ages, but more so in women in the group (39-47) years (Figure 1). Risk factors for  
169 incident include older age and family history. The sensitivity and specificity of MRI were (82.6%) and  
170 (73.2%) respectively (Table 2). This result was in line with a previous study conducted in ductal  
171 carcinoma, which also reveals the high sensitivity of MRI over mammography in detecting breast tumors  
172 [10].

173 Fat suppression is commonly used in MR imaging to suppress the signal from adipose tissue or detect  
174 adipose tissue. However, this technique is not specific for fat, and the signal intensity of tissue with a long  
175  $T_1$  and tissue with a short  $T_1$  may be ambiguous. Opposed-phase imaging is a fast and readily available  
176 technique [11]. The result of this study showed that breast cancer was more enhanced with fat  
177 suppression images (Figure 2), because this method suppressed the fat signal more potently and  
178 improved contrast and visibility of the breast lesions that embedded in fatty tissue [12].

179 In  $T_1$  and  $T_2$  relaxation times additively contribute to the contrast; therefore, also considering the inherent  
180 fat suppression, contrast is extremely good, and tissue with long  $T_1$  and long  $T_2$  may appear very bright  
181 [13].

182 Regarding signal intensity, the study showed that breast cancer has high signal intensity on  $T_1$  image  
183 (Table 3), while it has hypo or iso-signal intensity on  $T_2$  images. On  $T_2$  weighted images, fat has  
184 intermediate signal intensity. The signal intensity of remaining tissue depends on their water contents,  
185 and increases from the fibrous element which very low signal to glandular and ductal element to cystic  
186 lesions which have a very high signal intensity [14].

187 CE-MRI has been shown to be more sensitive than mammography in detecting DCIS. The study showed  
188 that most breast cancer cases have been enhanced, the result was in line with the study of Wiener et al,  
189 2004 [15], it showed that the primary index lesions, the sensitivity of MRI was (100%) in predicting a  
190 breast malignancy and the specificity was (73.7%) in predicting benign lesions. MRI detected an  
191 additional 37 lesions, of which 23 were cancerous, beyond those suspected on mammography or  
192 sonography [15].

193 The image subtraction technique was performed it showed that the cancer has heterogeneous features  
194 (89.9%), and ring enhancement was clearly seen on (8.7%). This result in line with the previous studies  
195 as speculated or irregular margin is suspicious for carcinoma where a smooth margin is more suggestive  
196 of benign lesion [16].

197 DCE-MRI has been used to evaluate focal breast lesions (Table 5). Adding information derived from the  
198 kinetic curve type of the architectural features of a lesion, improves the specificity of breast MRI [17]. By  
199 categorizing the type of the enhancement curve either as an absolute change in percentage  
200 enhancement, significantly greater values were seen compared with the qualitative method. In this study  
201 only 100 patients were selected for DCE-MRI, it revealed that most cases of cancer represented on type  
202 111 curve or rapid wash out. However, quantitative measurements of kinetic curve type resulted in  
203 significantly higher diagnostic performance and increasing specificity of MRI.

204 It was stated that DCE-MRI imaging has high negative predictive value in excluding breast cancer, so it  
205 plays a role in the evaluation of selected clinical and imaging findings of the breast, especially when  
206 biopsy is not technically feasible. Case selection is very important in ensuring the efficacy of this use of  
207 MR imaging because of potential false-positive and false-negative results [18]. In our study the overall  
208 sensitivity of DEC-MRI, ultrasound, and mammography was 82.7%; 82.6%, 68.0%; 30.4% and 60.0%;  
209 37.7% for both benign and malignant breast lesions respectively (Table 2) .Their specificity was 73.2%,  
210 75.6%, and 73.2% respectively (Table 2). DEC-MRI was the most sensitive imaging method for detection  
211 of cancer but with limited specificity due to overlap in features of benign and malignant lesions.

212 The main additional diagnostic value of DEC-MRI relies on detecting foci of multifocal, multicentric or  
213 contra-lateral disease unrecognized on conventional assessment (physical examination, mammography  
214 and ultrasound); recognition of invasive components in ductal carcinoma in situ (DCIS); assessing the  
215 response to neoadjuvant chemotherapy (NAC); detecting an occult primary breast cancer in patients  
216 presenting with metastatic cancer in axillary nodes; and detection of cancer in dense breast tissue [19].  
217 DCE-MRI is an emerging imaging method to enable the depiction of physiologic alterations and to assess

218 tumor angiogenesis [20]. This angiogenesis have been often too small to be proved by another imaging  
219 method [21]. Among the limitations of breast MRI are its higher cost, longer examination time, and lower  
220 availability compared with mammography and ultrasound [22].

221

## 222 5. CONCLUSION

223

224 In conclusion, the accuracy of MRI in this study was more than other imaging modalities in characterizing  
225 breast abnormalities and tumors. Therefore, it offers a new method to detect breast cancer in its early  
226 stage, and help improve the survival rate.

227

## 228 CONSENT

229

230 All authors declare that written informed consent was obtained from the patient (or other approved  
231 parties) for publication of this case report and accompanying images. A copy of the written consent is  
232 available for review by the Editorial office/Chief Editor/Editorial Board members of this journal.

233

234

## 235 ETHICAL APPROVAL

236

237 All authors hereby declare that all experiments have been examined and approved by the appropriate  
238 ethics committee and have therefore been performed in accordance with the ethical standards laid down  
239 in the 1964 Declaration of Helsinki.

240

241

## 242 REFERENCES

243

244 1. Morris EA, Schwartz LH, Dershaw DD, Van Zee KJ, Abramson AF, Liberman L. MR imaging of the  
245 breast in patients with occult primary breast carcinoma. *Radiology*. 1997;205(2):437-40.

246 <http://dx.doi.org/10.1148/radiology.205.2.9356625>

247 2. Elamin A1, Ibrahim ME, Abuidris D, Mohamed KE, Mohammed SI. Part I: cancer in Sudan-burden,  
248 distribution, and trends breast, gynecological, and prostate cancers. *Cancer Med*. 2015;4(3):447-56.

249 <http://dx.doi.org/10.1002/cam4.378>

250 3. Lehman CD, Lee AY, Lee CI. Imaging management of palpable breast abnormalities. *AJR Am J*  
251 *Roentgenol*. 2014;203(5):1142-53. <http://dx.doi.org/10.2214/AJR.14.12725>

252 4. Hegenscheid K, Schmidt CO, Seipel R, Laqua R, Ohlinger R, Hosten N, et al. Contrast enhancement  
253 kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral  
254 contraceptives, and postmenopausal hormone therapy. *Eur Radiol*. 2012;22(12):2633-40.

255 <http://dx.doi.org/10.1007/s00330-012-2544-9>

256 5. Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, et al. Clinical breast examination:  
257 practical recommendations for optimizing performance and reporting. *CA Cancer J Clin*. 2004;54(6):327-  
258 44. <http://dx.doi.org/10.3322/canjclin.54.6.327>

259 6. Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years a systematic  
260 review of observational evidence. *Prev Med*. 2011;53(3):108-14.

261 <http://dx.doi.org/10.1016/j.yjmed.2011.07.004>

262 7. Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, et al. SPIO-enhanced magnetic  
263 resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography  
264 lymphography in patients with breast cancer. *Ann Surg Oncol*. 2011;18(12):3422-9.

265 <http://dx.doi.org/10.1245/s10434-011-1710-7>

266 8. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in  
267 vivo proton MR spectroscopy--initial results. *Radiology* 2001; 220(1):40-6.

268 <http://dx.doi.org/10.1148/radiology.220.1.r01j10240>

269 9. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on  
270 quantification, validation and human studies. *Clin Radiol*. 2001;56(8):607-20.

271 <http://dx.doi.org/10.1053/crad.2001.0762>

- 272 10. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic  
273 review of incidence, treatment, and outcomes. *J Natl Cancer Inst.* 2010;102(3): 170-8.  
274 <http://dx.doi.org/10.1093/jnci/djp482>
- 275 11. Delfaut EM, Beltran J, Johnson G, Rousseau J, Marchandise X, Cotten A. Fat suppression in MR  
276 imaging: techniques and pitfalls. *Radiographics.* 1999;19(2):373-82.  
277 <http://dx.doi.org/10.1148/radiographics.19.2.g99mr03373>
- 278 12. Kul S, Cansu A, Alhan E, Dinc H, Reis A, Çan G. Contrast-enhanced MR angiography of the breast:  
279 Evaluation of ipsilateral increased vascularity and adjacent vessel sign in the characterization of breast  
280 lesions. *AJR Am J Roentgenol.* 2010;195(5):1250-4. <http://dx.doi.org/10.2214/AJR.10.4368>
- 281 13. Nazarpour M. The effect of inversion times on the minimum signal intensity of the contrast agent  
282 concentration using inversion recovery t1-weighted fast imaging sequence. *Med J Islam Repub Iran.*  
283 2014;28:128.
- 284 14. Kuhl CK, Klaschik S, Mielcarek P, Gieseke J, Wardelmann E, Schild HH. Do T2-weighted pulse  
285 sequences help with the differential diagnosis of enhancing lesions in dynamic breast MRI? *J Magn*  
286 *Reson Imaging.* 1999;9(2):187-96. [http://dx.doi.org/10.1002/\(SICI\)1522-2586\(199902\)9:2<187::AID-](http://dx.doi.org/10.1002/(SICI)1522-2586(199902)9:2<187::AID-)  
287 [JMRI6>3.3.CO;2-U](http://dx.doi.org/10.1002/(SICI)1522-2586(199902)9:2<187::AID-JMRI6>3.3.CO;2-U)
- 288 15. Wiener JI, Schilling KJ, Adami C, Obuchowski NA. Assessment of suspected breast cancer by MRI: a  
289 prospective clinical trial using a combined kinetic and morphologic analysis. *AJR Am J Roentgenol.*  
290 2005;184(3):878-86. <http://dx.doi.org/10.2214/ajr.184.3.01840878>
- 291 16. Deurloo EE, Peterse JL, Rutgers EJ, Besnard AP, Muller SH, Gilhuijs KG. Additional breast lesions in  
292 patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential  
293 benefit of computerised analysis. *Eur J Cancer.* 2005;41(10):1393-401.  
294 <http://dx.doi.org/10.1016/j.ejca.2005.03.017>
- 295 17. Cheng L, Li X. Breast magnetic resonance imaging: kinetic curve assessment. *Gland Surg.*  
296 2013;2(1):50-3.
- 297 18. Leung J. MR Imaging in the evaluation of equivocal clinical and imaging findings of the breast. *MRI*  
298 *Clin N Am.* 2010;18(2):295-308. <http://dx.doi.org/10.1016/j.mric.2010.02.012>
- 299 19. Menezes GL, Bosch VD, Postma EL, El Sharouni MA, Verkooijen HM, Diest JV, et al. Invasive  
300 ductolobular carcinoma of the breast: spectrum of mammographic, ultrasound and magnetic resonance  
301 imaging findings correlated with proportion of the lobular component. *Springerplus.* 2013;2:621.  
302 <http://dx.doi.org/10.1186/2193-1801-2-621>
- 303 20. Türkbey B, Thomasson D, Pang Y, Bernardo M, Choyke PL. The role of dynamic contrast-enhanced  
304 MRI in cancer diagnosis and treatment. *Diagn Interv Radiol.* 2010;16(3):186-192.
- 305 21. Houserkova D, Prasad SN, Svach I, Kucerova L, Duskova M, Bucil J, et al. The value of dynamic  
306 contrast enhanced breast MRI in mammographically detected BI-RADS 5 microcalcifications. *Biomed Pap*  
307 *Med Fac Univ Palacky Olomouc.* 2008;152(1):107-115. <http://dx.doi.org/10.5507/bp.2008.017>
- 308 22. DeMartini W, Lehman C, Partridge S. Breast MRI for Cancer Detection and Characterization: A  
309 Review of Evidence-Based Clinical Applications. *Acad Radiol.* 2008;15(4):408-416.  
310 <http://dx.doi.org/10.1016/j.acra.2007.11.006>